BONST
EW icon

Bank of Nova Scotia Trust’s Edwards Lifesciences EW Stock Holding History

Bank of Nova Scotia Trust’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,800
Closed -$66K – 212
2017
Q3 		$66K Buy
+1,800
New +$68.7K 0.01% 222

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Bank of Nova Scotia Trust's EW Position: Q4 2017 in Review

Bank of Nova Scotia Trust sold out of Edwards Lifesciences (EW) in Q4 2017, closing a stake of 1,800 shares — an estimated $66K sold.

Bank of Nova Scotia Trust first reported a position in EW in Q3 2017 and held it in 1 quarter. The position peaked at $66K in Q3 2017. 773 funds tracked by Wall St. Rank hold EW as of Q4 2017.

  • Bank of Nova Scotia Trust reported no remaining Edwards Lifesciences position as of Q4 2017 after selling out during the quarter.
  • Bank of Nova Scotia Trust sold 1,800 Edwards Lifesciences shares in Q4 2017, an estimated $66K.
  • Bank of Nova Scotia Trust first reported a position in Edwards Lifesciences in Q3 2017 and held it in 1 quarter.
  • Bank of Nova Scotia Trust's Edwards Lifesciences position peaked at $66K in Q3 2017.
  • 773 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2017.

Based on Bank of Nova Scotia Trust's 13F filing for Q4 2017, filed 13 Feb 2018.